EUCTR2021-001015-82-ES进行中（未招募）1 期
A multicenter, randomized, controlled, open-label, rater-blinded study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of ALXN1840 versus standard of care in pediatric participants with Wilson disease.
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Participants are eligible to be included in the study only if all of the following criteria apply:
- •1. Participants must be aged 3 to <18 years at time of signing the informed consent/assent.
- •Type of Participants and Disease Characteristics
- •2. Established diagnosis of WD by Leipzig-Score = 4 documented by testing as outlined in the 2012 European Association for the Study of Liver WD Clinical Practice Guidelines (Ferenci, 2003; EASL, 2012). Note: Historical test results for WD, including some or all of the following: presence of KF rings, neurologic symptoms, serum ceruloplasmin below the reference range, Coombs-negative hemolytic anemia, elevated liver or urinary copper, presence of mutations in the ATP7B gene, or other, as considered appropriate, may be used instead to confirm the diagnosis of Wilson disease.
- •3. Participant's parent/proxy must be willing and able to give written informed consent and the participant must be willing to give written informed assent (if applicable as determined by the central or local Institutional Review Board [IRB]/Institutional [or Independent] Ethics Committee [IEC]). If allowable per local regulations, a participant’s Legally Acceptable Representative (LAR) may provide informed consent if a participant is unable to do so.
- •4. Adequate venous access to allow collection of required blood samples.
- •5. Able to swallow intact ALXN1840 tablets or mini-tablets. Participants who require gastrostomy devices for feeding or medications may be enrolled upon agreement by the Medical Monitor.
- •6. Willing to avoid intake of foods and drinks with high contents of copper throughout the study duration
- •7. Female participants of childbearing potential and male participants must follow protocol-specified contraception guidance as described in Section 10.4 of the protocol.
- •Informed Consent
- •8. Capable of giving signed informed consent or assent as described in Section 10.1.3 of the protocol, which includes compliance with the requirements and restrictions listed in the informed consent or assent form and in this protocol.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 48
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •Medical Conditions
- •1. Decompensated hepatic cirrhosis.
- •2. MELD score > 13 (ages 12 to <18) or PELD score > 13 (ages 3 to < 12).
- •3. Modified Nazer score > 7.
- •4. Clinically significant gastrointestinal (GI) bleed within past 3 months
- •5. Alanine aminotransferase (ALT) > 2 × upper limit of normal (ULN) for participants treated for > 28 days with WD therapy (Cohort 1).
- •6. ALT > 5 × ULN for treatment naïve participants or participants who have been treated for = 28 days (Cohort 2)
- •7. Marked neurological disease requiring either nasogastric feeding tube or intensive inpatient medical care.
- •8. Hemoglobin less than lower limit of the reference range for age and sex.
- •9. History of seizure activity within 6 months prior to informed consent/assent.
- •Prior/Concomitant Therapy
- •10. Previous use of ALXN1840 or ammonium tetrathiomolybdate; concomitant use of penicillamine, trientine, or zinc (for participants randomized to ALXN1840).
- •Prior/Concurrent Clinical Study Experience
- •11. The use of an investigational drug within 30 days before initiation of the first dose of study intervention.
- •Diagnostic assessments
- •12. Participants in renal failure, defined as in end-stage renal disease on dialysis (chronic kidney disease stage 5 [CKD 5]) or estimated glomerular filtration rate < 30 mL/min/1.73m2.
- •13. Active infection with hepatitis B virus (positive hepatitis B surface antigen) or C virus (participants with positive hepatitis C antibody result would require confirmation of active disease with a positive hepatitis C polymerase chain reaction test), or seropositivity for HIV.
- •14. Any disability acquired from trauma or another illness that, in the opinion of the Investigator, could interfere with evaluation of disability due to WD.
- •15. Systemic disease or other illness, or any deviation in laboratory values that are confirmed on re-examination to be clinically significant by the Investigator that would, in the opinion of the Investigator, compromise participant safety or interfere with the collection or interpretation of study results.
- •Other Exclusions
- •16. Pregnant (or females who are planning to become pregnant) or breastfeeding females.
- •17. Known sensitivity to ALXN1840, ALXN1840 excipients (anhydrous di-calcium phosphate, anhydrous sodium carbonate), or any of the ingredients contained in ALXN1840 or related compounds.
- •18. Regular alcohol consumption within 6 months prior to the study defined as > 14 units for males or > 7 units for females per week. One unit is equivalent to 14 g of alcohol: a half pint (approx. 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
- •19. Abuse of illicit or prescribed drugs.
- •20. In the opinion of the Investigator, the participant and/or their parent/proxy is likely to be non-compliant or uncooperative during the study.
研究者
相似试验
进行中（未招募）
1 期
Phase 3, open-label study of ALXN1840 versus standard of care in pediatric participants with Wilson diseaseWilson DiseaseMedDRA version: 20.0Level: LLTClassification code 10047988Term: Wilson's diseaseSystem Organ Class: 100000004850EUCTR2021-001015-82-PLAlexion Pharmaceuticals, Inc.48
进行中（未招募）
3 期
Phase 3, open-label study of ALXN1840 versus standard of care in pediatric participants with Wilson diseaseWilson diseaseJPRN-jRCT2011210038Kobayashi Hiroshi48
进行中（未招募）
1 期
Phase 3, open-label study of ALXN1840 versus standard of care in pediatric participants with Wilson diseaseEUCTR2021-001015-82-DEAlexion Pharmaceuticals, Inc.40
进行中（未招募）
不适用
A multicenter, open-label, randomized, controlled, two-arm study to assess compliance with daily tablet intake of women on treatment with the oral contraceptive SH T00186D/BAY 86-5300 (0.02 mg ethinyl estradiol as betadex clathrate and 3 mg drospirenone) in a flexible extended regimen supported by a dispenser (CADDY) with a reminder function over 12 months - EU-Compliance by buzzer study of YAZ Flex in the CADDYContraceptionMedDRA version: 12.1Level: LLTClassification code 10030970Term: Oral contraceptionEUCTR2010-019902-17-DEBayer HealthCare AG500
进行中（未招募）
不适用
A multicenter, open-label, randomized, controlled, two-arm study to assess compliance with daily tablet intake of women on treatment with the oral contraceptive SH T00186D/BAY 86-5300 (0.02 mg ethinyl estradiol as betadex clathrate and 3 mg drospirenone) in a flexible extended regimen supported by a dispenser (CADDY) with a reminder function over 12 months - EU-Compliance by buzzer study of YAZ Flex in the CADDYContraceptionMedDRA version: 9.1Level: PTClassification code 10030970EUCTR2010-019902-17-ITBayer HealthCare AG500